Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase

Current Topics in Medicinal Chemistry

Volumn 4, Issue 10, 2004, Pages 1035-1044

  Painter, George R ^a   Almond, Merrick R ^a   Mao, Shuli ^b   Liotta, Dennis C ^b  

^a Chemerix Inc   (United States)

^b Chemistry Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMDOXOVIR; DIDANOSINE; DOUBLE STRANDED DNA; ELVUCITABINE; EMTRICITABINE; GAG PROTEIN; GENOMIC RNA; LAMIVUDINE; NUCLEOSIDE ANALOG; POL PROTEIN; POLYPEPTIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS ENVELOPE PROTEIN; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; BIOCHEMISTRY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DNA SYNTHESIS; DRUG ACTIVITY; DRUG APPROVAL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PURIFICATION; FATIGUE; GASTROINTESTINAL DISEASE; GENE MUTATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIVER FAILURE; MOLECULAR WEIGHT; MYOPATHY; NAUSEA; PANCREATITIS; PERIPHERAL NEUROPATHY; PROVIRUS; REVIEW; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; VIRUS PARTICLE; VIRUS REPLICATION;

ADENINE; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; DEOXYCYTIDINE MONOPHOSPHATE; DEOXYRIBONUCLEOTIDES; DIOXOLANES; DNA, VIRAL; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; KINETICS; MOLECULAR STRUCTURE; NUCLEOSIDES; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PURINE NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTRATE SPECIFICITY; ZALCITABINE;

EID: 3042801756     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388358     Document Type: Review

References (52)

1. Anonymous. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men, New York City and California. MMWR Morb. Mortal. Wkly. Rep. 1981, 30, 305-308.
2. Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 1983, 220, 868-871.
3. Gallo, R.C. et al. Isolation of human T-cells leukemia virus in acquired immunodeficiency syndrome (AIDS). Science 1983, 220, 865-867.
4. Carpenter CC, Cooper, D.A., Fishl, M.A. et al. Antiretroviral therapy in adults, updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283, 381-390.
5. Koszalka, G.W., Daluge, S.M., Boyd, F.L. Advances in Nucleoside and Nucleotide Antiviral Therapies. Annual Reports in Medicinal Chemistry, Academic Press NY, NY. 1998, 33, 163-171.
6. Cihlar, T., Bischofberger, N. Chapter 16. Recent Developments in Antiretroviral Therapies, Annual Reports in Medicinal Chemistry, Academic Press NY, NY. 2000, 35, 177-189.
7. De Clercq. Highlights in the development of new antiviral agents. Biochimica et Biophysica Acta 2002, 1587, 258-275.
8. Freed, E.O., Malcolm, M.A. In Fields Virology Vol. 2, Knipe DM and Howley PM. Eds, Lippincott Williams & Wilkins, Philadelphia, 2001, 1971.
9. Physicians Desk Reference, Ed. 55, 2001.
10. Hoffman, A.D., Banapour, B., Levy, J.A. Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 1985, 147, 326-335.
11. Veronese, F. DiMarzo Copeland, T.D., DeVico, A.L., Rahman, R., Oroszlan, S., Gallo, R.C., Sarngadharan, M.G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231, 1289-1291.
12. Starnes, M., Gao, W., Ting, R., Cheng, Y. Enzyme activity gel analysis of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 1988, 263, 5132-5134.
13. Hizi, A., McGill, C., Hughes, S.H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc. Natl. Acad. Sci. USA 1988, 85, 1218-1222.
14. Tisdale, M., Ertl, P., Larder, B.A., Purifoy, D.J.M., Darby, G., Powell, K.L. Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function. J. Virol. 1988, 62, 3662-3667.
15. Bathurst, I.C., Moen, L.K., Lujan, M.A., Gibson, H.L., Feucht, P.H., Pichuantes, S., Craik, C.S., Santi, D.V., Barr, P.J. Characterization of the human immunodeficiency virus type-1 reverse transcriptase enzyme produced in yeast. Biochem. Biophys. Res. Commun. 1990, 171, 589-595.
16. Kohlstaedt, L.A., Wang, J., Friedman. J.M., Rice, P.A., Steitz, T.A. Crystal structure at 3.5. ANG. resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
17. Ollis, D.L., Brick, P., Hamlin, R., Xuong, N.G., Steitz, T.A. Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP. Nature 1985, 313, 762-766.
18. Huang, H., Chopra, R., Verdine, G.L., Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase, implications for drug resistance. Science 1998, 282, 1669-1675.
19. Doublié, S., Tabor, S., Long, A.M., Richardson, C.C., Ellenberger, T. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 A resolution. Nature 1998, 391, 251-258.
20. Reardon, J.E. Human immunodeficiency virus reverse transcriptase, steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 1992, 31, 4473-4479.
21. Hsieh, J.C., Zinnen, S., Modrich, P. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 1993, 268, 24607-24613.
22. Kati, W.M., Johnson, K.A., Jerva, L.F., Anderson, K.S. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 1992, 267, 25988-25997.
23. Kerr, S.G., Anderson, K.S. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase, implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 1997, 36, 14064-14070.
24. Spence, R.A., Kati, W.M., Anderson, K.S., Johnson, K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
25. Rittinger, K., Divita, G., Goody, R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 1995, 92, 8046-8049.
26. Hopkins, S., Furman, P.A., Painter, G.R. Investigation of the stereochemical course of DNA thesis catalysed by human immunodeficiency virus type 1 reverse transcriptase. Biochem. Biophys. Res. Commun. 1989, 163, 106-110.
27. Painter, G.R., Wright, L.L., Hopkins, S., Furman, P.A. Initial binding of 2′-deoxynucleoside 5′-triphosphates to human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 1991, 266, 19362-19368.
28. Feng, J.Y., Anderson, K.S. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 1999, 38, 55-63.
29. Majumdar, C., Abbotts, J., Broder, S., Wilson, S.H. Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J. Biol. Chem. 1988, 263, 15657-15665.
30. Ferrin, L.J., Mildvan, A.S. Nuclear Overhauser effect studies of the conformations and binding site environments of deoxynucleoside triphosphate substrates bound to DNA polymerase I and its large fragment. Biochemistry 1985, 24, 6904-6913.
31. Brautigam, C.A., Steitz, T.A. Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes. Curr. Opin. Struct. Biol. 1998, 8, 54-63.
32. Steitz, T.A. DNA- and RNA-dependent DNA polymerases. Curr. Opin. Struct. Biol. 1993, 3, 31-38.
33. Johnson, K.A. Conformational coupling in DNA polymerase fidelity. Annual Review of Biochemistry 1993, 62, 685-713.
34. Reardon, J.E. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J. Biol. Chem. 1993, 268, 8743-8751.
35. Patel, S.S., Wong, I., Johnson, K.A. Pre-steady-state kinetic analysis of processive DNA replication including complete characterization of an exonuclease-deficient mutant. Biochemistry 1991, 30, 511-525.
36. Furman, P.A., Painter, G.R., Anderson, K.S. An analysis of the catalytic cycle of HIV-1 reverse transcriptase, opportunities for chemotherapeutic intervention based on enzyme inhibition. Current Pharmaceutical Design 2000, 6, 547-567.
37. Pottage, J., Thompson, M., Kahn, J., Delehanty, J., McCreedy, B., Rousseau, F. 1998, in 12th World AIDS Conference in Geneva.
38. Lacey, S.F., Reardon, J.E., Furfine, E.S., Kunkel, T.A., Bebenek, K., Eckert, K.A., Kemp, S.D., Larder, B.A. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 1992, 267, 15789-15794.
39. Reardon, J.E., Miller, W.H. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′ -triphosphate. J. Biol. Chem. 1990, 265, 20302-20307.
40. Carroll, S.S., Geib, J., Olsen, D.B., Stahlhut, M., Shafer, J.A., Kuo, L.C. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine, triphosphate. Biochemistry 1994, 33, 2113-2120.
41. Krebs, R., Immendörfer, U., Thrall, S.H., öhrl, B.M., Goody, R.S. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 1997, 36, 10292-10300.
42. Vaccaro, J.A., Parnell, K.M., Terezakis, S.A., Anderson, K.S. Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP, an equivalent incorporation efficiency relative to the natural substrate dTTP. Antimicrob. Agents Chemother. 2000, 44, 217-221.
43. Krishnan, P., Fu, Q., Lam, W., Liou, J.-Y., Dutschman, G., Cheng, Y.-C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates, selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 2002, 277, 5453-5459.
44. Cheng, Y.-C. Potential use of antiviral 1(-)nucleoside analogues for the prevention or treatment of viral associated cancers. Cancer Lett. 2001, 162, S33-S37.
45. Painter, G.R., Furman, P.A., Rimsky, L.T., Schinazi, R.F., Quinn, J.B. Preclinical and clinical development of the Anti-HIV, Anti-HBV oxathiolane nucleoside analog emtricitabine. Frontiers in Viral Hepatitis (Eds. Schinazi R, Sommadossi JP, Thomas HC), International Medical Press, London (2002).
46. Richman, D.D. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Therapy 2001, 6, 83-88.
47. Thompson, M., Kessler, H., Eron, J., Deeks, S., Andunio, R., Jacobson, J., Sista, N., Quinn, J., Klish, C., Bigley, J., Rousseau, F. Reduction in HIV Viral Load after Short Term Monotherapy with DAPD. Poster presented at, Infectious Diseases Society of America 2000 (IDSA), September 7-10, New Orleans, LA.
48. Furman, P.A., Kiefer, L., Jeffrey, J., Feng, J., Anderson, K.S., Borroto-Esoda, K., Hill, E., Liberman, I., Sommadossi, J.P., Chu, C.K., Copeland, W., Schinazi, R.S., Painter, G.P. Mechanism of Action of 2,6-diaminopurine Dioxolane, A prodrug of the HIV-1 Inhibitor Dioxolane Guanosine. Antimicrob. Agents Chemother. 2001, 45, 158-165.
49. Schinazi, R.F., Mellors, J., Bazmi, H., Siamond, S., Garber, S., Gallagher, K., Geleziunas, R., Klabe, R., Pierce, M., Rayner, M., We, J.T., Zhang H, Hammond J, Bacheler L, Manion J, Otto MJ, Stuyver L, Trainor G, Liotta D, Erickson-Vittanen S. DPC 817, a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 2002, 46, 1394-1401.
50. Gazzard, B.G. The Potential Place of Tenofovir in Antiretroviral Treatment Regimens. Int J. Clin. Pract. 2001, 55(10), 704-709.
51. Food and Drug Administration, Center for Drug Evaluation and Research Antiviral Drugs Advisory Committee, NDA 21-356, Viread™ Tablets, Gilead Sciences, Inc. Proposed for the treatment of human immunodeficiency virus (HIV) infection. October 3, 2001.
52. Wang, J., Smerdon, S., Jager, J., Kohlstaedt, L.A., Rice, P.A., Friedman, J.M., Steitz, T.A. Structural basis of asymmetry in the human immunodefiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. USA 1994, 91, 7242-7246.